Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine

Reuters

2025/05/28

<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine

Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538476829"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538476829\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538476829?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538476829","market":"nz","top_or_hot":-1,"title":"Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-28 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日興方舟顛覆性創新基金B SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLc6RlyN:1","article_id":"2538476829","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538476829","pubTimestamp":1748435427,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.Disclaimer: This news brief was created by Public Technologies  using generative artificial int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4613":"AI应用软件","TEM":"Tempus AI","BK4611":"AI医疗","BK4121":"生命科学工具和服务"},"translate_title":"Tempus AI Inc.庆祝发现十周年，开展1,500个研究项目推进精准医疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":0.9},"content_text":"Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n    \n\n        Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}